SAR 446422
Alternative Names: SAR-446422Latest Information Update: 19 Feb 2024
At a glance
- Originator Sanofi
- Class Anti-inflammatories; Bispecific antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Inflammation